What is SolasCure?
Founded in 2017, SolasCure is dedicated to enhancing patient outcomes and reducing healthcare costs through its pioneering wound care products. The company's flagship innovation, Aurase, is a hydrogel incorporating a highly specific enzyme derived from medical maggots. This enzyme is designed to accelerate wound cleaning, thereby promoting faster healing and improving the overall well-being of patients suffering from chronic wounds. SolasCure operates within the critical intersection of biotechnology and healthcare, aiming to revolutionize the treatment of complex wound conditions.
How much funding has SolasCure raised?
SolasCure has raised a total of $35.8M across 3 funding rounds:
Series A
$20.8M
Unspecified
$1.6M
Series B
$13.4M
Series A (2021): $20.8M with participation from Development Bank of Wales, Bionova Capital, Seneca Partners, Jonathan Milner, Eva Pharma, BRAIN Biotech AG, and François Fournier
Unspecified (2021): $1.6M led by Seneca Partners
Series B (2023): $13.4M supported by Wealth Club, Seneca Partners, Eva Pharma, and Brain
Key Investors in SolasCure
Development Bank of Wales
The Development Bank of Wales provides sustainable and effective business finance solutions for companies based in or relocating to Wales. They offer a range of services including business loans, equity finance, and support for various business needs such as starting, growing, and developing technology ventures.
Bionova Capital
Bionova Capital is an investment firm that likely focuses on early-stage biotechnology and life sciences companies, providing crucial seed and venture capital to fuel innovation and growth in the sector.
Seneca Partners
Seneca Partners is a leading independent sponsor specializing in lower-middle market opportunities, working with family offices and institutional capital partners to invest in profitable businesses across various sectors, including healthcare services and technology.
What's next for SolasCure?
The recent major strategic investment positions SolasCure for accelerated development and commercialization of its proprietary technologies. With a clear focus on improving patient care and addressing significant healthcare costs associated with chronic wounds, the company is poised to expand its market reach. Future endeavors will likely involve scaling production, further clinical validation, and broader market adoption of Aurase and other pipeline innovations. This capital infusion is expected to fuel strategic partnerships and research initiatives, solidifying SolasCure's role as a key player in the advanced wound care sector.
See full SolasCure company page
